Rejection therapies.
One hundred thirty-eight primary liver allograft recipients received cyclosporine and prednisolone immunosuppression with azathioprine added during the induction phase. All rejections were biopsy-confirmed clinical rejections. Acute rejection was seen in 58.7% of the patients. The treatment of acute rejection was successful in 88.9% of treated patients. Rejection-related death was seen in 4.3%, and retransplantation was performed for acute or chronic rejection in 2.2% of the patients. The risk for dying increased with the number of rejection treatments.
Klintmalm
G B
GB
Department of Surgery, Baylor University Medical Center, Dallas, Texas 75246.
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D016031:Liver Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012086:Reoperation
D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D006854:Hydrocortisone; D008775:Methylprednisolone